Novo Nordisk Projects Slower Growth for 2025, Targets CagriSema Approval in 2026

Novo Nordisk expects sales growth of 16-24% at constant exchange rates (CER) for 2025, lower than the 26% growth achieved in 202416.

The company plans to submit its next-generation obesity drug CagriSema for regulatory approval in the first quarter of 202627.

Novo Nordisk reported strong performance in 2024, with net sales reaching 290,403 million DKK, a 25% increase from 20231.

Wegovy, Novo Nordisk's current best-selling weight loss drug, doubled its sales in Q4 20246.

The company is initiating a new Phase 3 trial (REDEFINE 11) for CagriSema in the first half of 2025 to explore further weight loss potential5.

Novo Nordisk's stock price is projected to increase to $155.46 by 2025, representing a 13.68% increase from its current value4.

The company is focusing on expanding its production capacity and progressing its R&D pipeline, including obesity projects such as CagriSema and amycretin1.

Sources:

1. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915255

2. https://medwatch.com/News/regulation/article17874936.ece

4. https://www.benzinga.com/money/ozempic-novo-nordisk-stock-price-prediction

5. https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/q4-2024-investor-presentation.pdf

6. https://www.fiercepharma.com/pharma/novo-nordisk-predicts-milder-sales-growth-2025-after-obesity-star-wegovy-doubles-numbers-q4

7. https://www.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1412980/news/Novo-Nordisk-to-seek-regulatory-approval-for-CagriSema-obesity-drug-early-2026-48961961/